Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jul;31(7):961-964.
doi: 10.1016/j.annonc.2020.03.300. Epub 2020 Apr 2.

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

J-M Michot  1 , L Albiges  2 , N Chaput  3 , V Saada  4 , F Pommeret  2 , F Griscelli  4 , C Balleyguier  5 , B Besse  2 , A Marabelle  6 , F Netzer  7 , M Merad  2 , C Robert  2 , F Barlesi  2 , B Gachot  8 , A Stoclin  8
Affiliations
Case Reports

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

J-M Michot et al. Ann Oncol. 2020 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure JMM reports sponsored research at Gustave Roussy Cancer Center with Abbvie, Agios, Amgen, Astex, AstraZeneca, Bayer, Beigene, Blueprint, Bristol-Myers Squibb, Boeringer Ingelheim, Celgene, Chugai, Forma, Genentech, GSK, H3 Biomedecine, Incyte, Innate Pharma, Janssen, Lilly, Loxo, Medimmune, MSD, Novartis, Oncopeptides AB, Roche, Sanofi, Taiho, and Xencor, outside the submitted work, and personal fees or travel grants or ad-board: Astex, Iqone, Mundipharma, and Bristol-Myers Squibb, outside the submitted work. BB reports sponsored research at Gustave Roussy Cancer Center with Abbvie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE immunotherapeutics, Pfizer, Pharma Mar, Roche-Genentech, Sanofi, Servier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, and Tolero Pharmaceuticals, outside the submitted work. CR reports personal fees for advisory boards from Bristol-Myers Squibb (BMS), Pierre Fabre, Novartis, Amgen, Merck, and Roche, outside the submitted work. FB reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer, and Takeda, outside the submitted work. AM reports sponsored research at Gustave Roussy Cancer Center with: Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveo pharmaceuticals, Bayer, Beigene, Blueprint, BMS, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GSK, H3 Biomedecine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, MSD, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides AB, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro, and Xencor, outside the submitted work.

Figures

Figure 1
Figure 1
Outcome of patient with COVID-19 before and after tocilizumab. The top of the figure shows evolution of clinical vital signs, requirement for supplemental O2 in l/min, C-reactive protein in blood. The bottom of the figure shows a pulmonary CT scan of the patient before (day 6) and after (day 12) tocilizumab. The patient received two doses of i.v. tocilizumab at 8 mg/kg for each dose (small black arrows). All therapies given for COVID-19 are summarized at the top of the figure. COVID-19, coronavirus disease 2019; CRP, C-reactive protein in blood; CT, computerized tomography; i.v., intravenously; Lopinavir/r, lopinavir plus ritonavir; O2L, oxygen supplementation in l/min; SpO2, saturation pulsed in oxygen; T°, temperature in degrees Celsius.
Figure 2
Figure 2
CD25 and HLA-DR expression among CD4+ and CD8+ T cells in blood of a patient with COVID-19 before and after tocilizumab. Percentage of HLA-DR (LT4 HLA-DR+) and CD25 (LT4 CD25+) among CD3+CD4+ (LT4) and of HLA-DR (LT8 HLA-DR+) and CD25 (LT8 CD25+) among CD3+CD8+ (LT8) before introduction of tocilizumab (Pre_TOCI) and 4 days after initiation of treatment (Post_TOCI). COVID-19, coronavirus disease 2019.
See this image and copyright information in PMC

References

    1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
    1. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539. - PMC - PubMed
    1. Wong C.K., Lam C.W.K., Wu A.K.L. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103. - PMC - PubMed
    1. Conti P., Ronconi G., Caraffa A. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (CoV-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(1):1. - PubMed
    1. Chen N., Zhou M., Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. - PMC - PubMed

MeSH terms